Treatment of urinary bladder cancer - A retrospective analysis

A. Kuten; Y. Cohen; R. Rubinov; M. Baz; J. Dale; N. Haim; E. Robinson

Treatment of urinary bladder cancer - A retrospective analysis

A. Kuten, Y. Cohen, R. Rubinov, M. Baz, J. Dale, N. Haim, E. Robinson

Research output: Contribution to journal › Article › peer-review

Abstract

Data on 482 stage A-0 - D2 bladder cancer patients referred between 1975-86 were analyzed. Prognosticators of survival were stage, histologic subtype and differentiation. 143 patients with disease localized to the pelvis (stage A-0 - D1) received definitive radiotherapy with 60 Gy or more, and 25 underwent preoperative irradiation and cystectomy. Later, a group of 56 selected patients with stage B - D1, referred between 1988-1991, received neo-adjuvant MCV chemotherapy (methotrexate, cisplatin and vinblastine) preceding either definitive radiotherapy or surgery. The 2-year overall actuarial survival rates were similar: 63% for radiotherapy only, 72% for cystectomy and 68% for neo-adjuvant chemotherapy; they were also similar when broken down by stage and grade.

Original language	English
Pages (from-to)	606-610+672
Journal	Harefuah
Volume	128
Issue number	10
State	Published - 1 Jan 1995
Externally published	Yes

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{78869746174241d698c0fd5aeaff807e,

title = "Treatment of urinary bladder cancer - A retrospective analysis",

abstract = "Data on 482 stage A-0 - D2 bladder cancer patients referred between 1975-86 were analyzed. Prognosticators of survival were stage, histologic subtype and differentiation. 143 patients with disease localized to the pelvis (stage A-0 - D1) received definitive radiotherapy with 60 Gy or more, and 25 underwent preoperative irradiation and cystectomy. Later, a group of 56 selected patients with stage B - D1, referred between 1988-1991, received neo-adjuvant MCV chemotherapy (methotrexate, cisplatin and vinblastine) preceding either definitive radiotherapy or surgery. The 2-year overall actuarial survival rates were similar: 63% for radiotherapy only, 72% for cystectomy and 68% for neo-adjuvant chemotherapy; they were also similar when broken down by stage and grade.",

author = "A. Kuten and Y. Cohen and R. Rubinov and M. Baz and J. Dale and N. Haim and E. Robinson",

year = "1995",

month = jan,

day = "1",

language = "English",

volume = "128",

pages = "606--610+672",

journal = "Harefuah",

issn = "0017-7768",

publisher = "Israel Medical Association",

number = "10",

}

TY - JOUR

T1 - Treatment of urinary bladder cancer - A retrospective analysis

AU - Kuten, A.

AU - Cohen, Y.

AU - Rubinov, R.

AU - Baz, M.

AU - Dale, J.

AU - Haim, N.

AU - Robinson, E.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - Data on 482 stage A-0 - D2 bladder cancer patients referred between 1975-86 were analyzed. Prognosticators of survival were stage, histologic subtype and differentiation. 143 patients with disease localized to the pelvis (stage A-0 - D1) received definitive radiotherapy with 60 Gy or more, and 25 underwent preoperative irradiation and cystectomy. Later, a group of 56 selected patients with stage B - D1, referred between 1988-1991, received neo-adjuvant MCV chemotherapy (methotrexate, cisplatin and vinblastine) preceding either definitive radiotherapy or surgery. The 2-year overall actuarial survival rates were similar: 63% for radiotherapy only, 72% for cystectomy and 68% for neo-adjuvant chemotherapy; they were also similar when broken down by stage and grade.

AB - Data on 482 stage A-0 - D2 bladder cancer patients referred between 1975-86 were analyzed. Prognosticators of survival were stage, histologic subtype and differentiation. 143 patients with disease localized to the pelvis (stage A-0 - D1) received definitive radiotherapy with 60 Gy or more, and 25 underwent preoperative irradiation and cystectomy. Later, a group of 56 selected patients with stage B - D1, referred between 1988-1991, received neo-adjuvant MCV chemotherapy (methotrexate, cisplatin and vinblastine) preceding either definitive radiotherapy or surgery. The 2-year overall actuarial survival rates were similar: 63% for radiotherapy only, 72% for cystectomy and 68% for neo-adjuvant chemotherapy; they were also similar when broken down by stage and grade.

UR - http://www.scopus.com/inward/record.url?scp=0029131740&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029131740

SN - 0017-7768

VL - 128

SP - 606-610+672

JO - Harefuah

JF - Harefuah

IS - 10

ER -

Treatment of urinary bladder cancer - A retrospective analysis

Abstract

ASJC Scopus subject areas

UN SDGs

Other files and links

Fingerprint

Cite this